Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis

Stauffer, Virginia L.; Lipkovich, Ilya; Hoffmann, Vicki Poole; Heinloth, Alexandra N.; McGregor, H Scott; Kinon, Bruce J.
January 2009
BMC Psychiatry;2009, Vol. 9, Special section p1
Academic Journal
Background: This study focuses on exploring the relationship between changes in appetite or eating behaviors and subsequent weight change for adult patients with schizophrenia or bipolar disorder treated with olanzapine and adjunctive potential weight mitigating pharmacotherapy. The aim is not to compare different weight mitigating agents, but to evaluate patients' characteristics and changes in their eating behaviors during treatment. Identification of patient subgroups with different degrees of susceptibility to the effect of weight mitigating agents during olanzapine treatment may aid clinicians in treatment decisions. Methods: Data were obtained from 3 randomized, double-blind, placebo-controlled, 16-week clinical trials. Included were 158 patients with schizophrenia or bipolar disorder and a body mass index (BMI) ≥ 25 kg/m² who had received olanzapine treatment in combination with nizatidine (n = 68), sibutramine (n = 42), or amantadine (n = 48). Individual patients were analyzed for categorical weight loss ≥ 2 kg and weight gain ≥ 1 kg. Variables that were evaluated as potential predictors of weight outcomes included baseline patient characteristics, factors of the Eating Inventory, individual items of the Eating Behavior Assessment, and the Visual Analog Scale. Results: Predictors/correlates of weight loss ≥ 2 kg included: high baseline BMI, low baseline interest in food, and a decrease from baseline to endpoint in appetite, hunger, or cravings for carbohydrates. Reduced cognitive restraint, increase in hunger, and increased overeating were associated with a higher probability of weight gain ≥ 1 kg. Conclusion: The association between weight gain and lack of cognitive restraint in the presence of increased appetite suggests potential benefit of psychoeducational counseling in conjunction with adjunctive pharmacotherapeutic agents in limiting weight gain during antipsychotic drug therapy. Trial Registration: This analysis was not a clinical trial and did not involve any medical intervention.


Related Articles

  • From Eating Disorder to Schizophrenia. Taycan, Serap Erdogan; Demir, Suleyman; Celikel, Feryal Cam // Dusunen Adam: Journal of Psychiatry & Neurological Sciences;Jun2013, Vol. 26 Issue 2, p225 

    A letter to the editor about the case of a 16-year-old female patient with the comorbidity of eating disorders with psychosis.

  • Metabolic Consequences and Vulnerability to Diet- Induced Obesity in Male Mice under Chronic Social Stress. Bartolomucci, Alessandro; Cabassi, Aderville; Govoni, Paolo; Ceresini, Graziano; Cero, Cheryl; Berra, Daniela; Dadomo, Harold; Franceschini, Paolo; Dell'Omo, Giacomo; Parmigiani, Stefano; Palanza, Paola // PLoS ONE;2009, Vol. 4 Issue 1, p1 

    Social and psychological factors interact with genetic predisposition and dietary habit in determining obesity. However, relatively few pre-clinical studies address the role of psychosocial factors in metabolic disorders. Previous studies from our laboratory demonstrated in male mice: 1)...

  • Adverse Reaction Research.  // Reactions Weekly;6/16/2007, Issue 1156, p2 

    The article presents several medical research. A study was published which shows that the treatment of schizophrenia with olanzapine is associated with a greater increase in body weight and blood glucose. Another study was done which tackles the effect of etoricoxib on the pharmacodynamics and...

  • Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Naing, Aung; Dalal, Shalini; Abdelrahim, Maen; Wheler, Jennifer; Hess, Kenneth; Fu, Siqing; Hong, David; Janku, Filip; Falchook, Gerald; Ilustre, Alyson; Ouyang, Fengying; Kurzrock, Razelle // Supportive Care in Cancer;Sep2015, Vol. 23 Issue 9, p2649 

    Background: Olanzapine is used for treatment of psychiatric conditions but causes substantial weight gain. This study assessed safety, efficacy, and changes in metabolic cytokines associated with olanzapine administration in patients with cachexia due to advanced cancer. Methods: Patients with...

  • NEWS BRIEFS.  // Healthy Weight Journal;May/Jun2001, Vol. 15 Issue 3, p34 

    Presents news briefs on body weight and nutrition, as of May 5, 2001. Efforts to develop a national action plan addressing the prevalence of overweight and obesity in the United States; Discussion on the genetic aspects of age-adjusted waist-to-hip ratio; Linkage between body building and...

  • Shall the anthropometry of physique cast new light on the diagnoses and treatment of eating disorders? Bartsch, Andreas Joachim; Brümmerhoff, Alexander; Greil, Holle; Neumärker, Klaus-Jürgen // European Child & Adolescent Psychiatry;2003 Supplement 1, Vol. 12, pi54 

    Body weight is crucial to eating disorders. Beyond gender, age, and height it is determined by anthropometric features of physique, i. e. somatotypes. We investigated their impact on the anthropometric and metabolic assessment of nutritional status, psychometrics, and other clinical aspects of...

  • Are Eating Disorders Culture-Bound?  // Eating Disorders Review;Nov/Dec2003, Vol. 14 Issue 6, p6 

    Examines the impact of culture on the development of certain eating disorder in Fiji. Association of binge eating with nontraditional Fijian attitude toward the body; Distinction of weight and diet from Western populations; Attitudes of the Fijian toward weight and body shape.

  • Olanzapina y terapia grupal cognitivo-conductual en trastorno límite de la personalidad.  // Actas Espanolas de Psiquiatria;mar-abr2001, Vol. 29 Issue 2, p85 

    No abstract available.

  • Effects of Olanzapine on Lipid Abnormalities in Elderly Psychotic Patients. Barak, Yoram; Aizenberg, Dov // Drugs & Aging;2003, Vol. 20 Issue 12, p893 

    Introduction: Recently concern regarding the cause or worsening of diabetes mellitus by some of the second-generation antipsychotics and their adverse affects on lipid metabolism has caused growing concern amongst physicians and patients. This study aims to assess these effects in elderly...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics